Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGogas, H.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorTsoutsos, D.en
dc.contributor.authorPanagiotou, P.en
dc.contributor.authorFrangia, K.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorCastana, O.en
dc.contributor.authorPolyzos, A.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorIoannovich, J.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectDisease Progressionen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectInterleukin-2/administration & dosageen
dc.subjectMelanoma/*drug therapy/pathology/secondaryen
dc.subjectMiddle Ageden
dc.subjectSalvage Therapyen
dc.subjectSkin Neoplasms/*drug therapy/pathologyen
dc.subjectSurvival Rateen
dc.subjectTime Factorsen
dc.subjectVinblastine/administration & dosage/*analogs & derivativesen
dc.titleVinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Groupen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractOBJECTIVES: To evaluate the efficacy and toxicity of the combination of vinorelbine and interleukin (IL)-2 in patients with metastatic melanoma as second-line chemotherapy. PATIENTS AND METHODS: Twenty-two patients with histologically confirmed stage IV melanoma previously treated with temozolomide-based chemotherapy--only one regimen of chemotherapy for disseminated disease was allowed--were treated with vinorelbine 30 mg/m2 on days 1 and 15 and IL-2 subcutaneous 9 x 10(6) once daily on days 2-6 and 16-19 every 4 weeks for maximum of six cycles. RESULTS: From January 2000 to July 2001, 22 patients entered the study; the median age was 56 years. Among 20 evaluable patients there were 2 (9.1%) objective responses including 1 complete response and 1 partial response. Five (22.7%) had stabilization of their disease, and 13 (59.1%) progressed. The median time to progression (TTP) was 2.9 months and the median overall survival was 9.1 months. There was a significant difference in TTP in patients who responded or remained stable (median TTP 10.75 months) and those who progressed (median TTP 2.1 months) (p<0.05). There was also a difference in survival in the two groups (p<0.05 (28 vs. 8 months). The most common side effects were flulike symptoms, such as fever, chills, fatigue, and injection site reaction. Grade 3 hematological toxicity rarely occurred. One patient discontinued therapy because of fatigue and anorexia. There were no treatment-related deaths. CONCLUSIONS: The combination of vinorelbine and IL-2 provides clinical benefit in patients recurring or progressing on first-line chemotherapy for metastatic melanoma, with manageable toxicity.en
heal.journalNameCancer Investen
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons